Courageous Science + Compassion
Apellis Pharmaceuticals (Nasdaq: APLS) is a clinical-stage and commercial-stage biopharmaceutical company focused on the complement system, a key branch of innate immunity. Founded in 2009 by Cedric Francois and Dinesh Bhatt, the company pioneered targeted C3 inhibition with its lead compound pegcetacoplan. Apellis received FDA approval for EMPAVELI for paroxysmal nocturnal hemoglobinuria (PNH) in 2021 and SYFOVRE for geographic atrophy (GA) in 2023 — the first approved treatment for GA. Headquartered in Waltham, Massachusetts.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2023
Nov 2017
Aug 2017
Feb 2016
Dec 2014
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
